Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look ...

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else ...

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the personal care industry, including Medifast (NYSE:MED) and its peers.

A new study suggests that women using menopause hormone therapy alongside GLP-1 medications like Wegovy may experience greater weight loss.

The Grammy winner wrote her 2025 song “The Mirror” about body dysmorphia and feeling comfortable in your own skin ...

Medifast, Inc. reported earnings results for the third quarter and nine months ended September 30, 2026. For the third quarter, the company reported sales was USD 72.05 million compared to USD 89.41 ...

Medifast (NYSE:MED) reported third-quarter 2026 revenue of $72 million, down 19.4% from a year earlier, as the company continued to face a sharp decline in its active earning coach base. Management sa ...

Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster ...

Medifast, Inc. provided earnings guidance for the fourth quarter and full year of 2026. For the quarter, the company expects fourth quarter 2026 revenue to be in the range of $55 million to ...

Could a new drug that makes fat cells self-destruct be the next big GLP-1? CBL-514 targets fat cells, and a new study shows that it was effective in slimming down participants’ waistlines. Early data ...

Scientists are exploring a new group of hormones—beyond GLP-1s—to target for weight loss.

Weight loss medications are not right for everyone, but more people qualify than you might think. Most adults can be ...